Table 2 Transplant outcomes between patients who underwent Haplo-SCT and those who received MSDT
Parameter | Haplo-SCT group (n = 169) | MSDT group (n = 39) | P value |
|---|---|---|---|
Median time of neutrophil engraftment (range) | 13 days (10–25 days) | 15 days (9–22 days) | 0.016 |
Platelet engraftment at day 100 post-transplantation | 95% (95% CI, 92–98%) | 100% | < 0.001 |
CMV reactivation at day 100 post-transplantation | 68% (95% CI, 61–75%) | 18% (95% CI, 6–30%) | < 0.001 |
EBV reactivation at day 100 post-transplantation | 15% (95% CI, 10–21%) | 0 | 0.011 |
Grades II–IV acute GVHD | 21% (95% CI, 17–27%) | 23% (95% CI, 10–36%) | 0.884 |
Total chronic GVHD | 44% (95% CI, 36–52%) | 48% (95% CI, 31–65%) | 0.850 |
Moderate-to-severe chronic GVHD | 18% (95% CI, 10–26%) | 27% (95% CI, 10–44%) | 0.192 |
Cumulative incidence of positive MRD after transplantation | 26% (95% CI, 19–33%) | 44% (95% CI, 28–60%) | 0.043 |
Three-year probability of relapse | 23% (95% CI, 17–29%) | 47% (95% CI, 31–63%) | 0.006 |
Three-year probability of NRM | 11% (95% CI, 6–16%) | 10% (95% CI, 1–19%) | 0.845 |
Three-year probability of LFS | 65% (95% CI, 58–72%) | 43% (95% CI, 27–59%) | 0.023 |
Three-year probability of OS | 68% (95% CI, 61–75%) | 46% (95% CI, 30–62%) | 0.039 |
Three-year probability of GRFS | 54% (95% CI, 46–62%) | 36% (95% CI, 21–51%) | 0.055 |